Company profilePharmaceutical#604 of 1,318 in Pakistan✓ No DRAP alerts

LCPW

Pharmaceutical company · 18 brands · 26 molecules

Ranked #2 of 5 companies in Peritoneal Dialytics

18 registered products 13 pharmaceutical brands 26 distinct molecules 0 DRAP alerts

Company overview

18
registered products
13
pharmaceutical brands
26
distinct molecules
12
therapeutic classes
0
DRAP alerts

LCPW is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 18 product registrations across 26 distinct molecules. Its portfolio is concentrated in Peritoneal Dialytics and Mydriatics And Cycloplegics. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Top molecules by brand count

Eye3 brands
Peritoneal Dialysis Solution2 brands
Atropine2 brands
Azithromycin Usp..250Mg1 brand
Azithromycin Usp....200Mg1 brand
Fluoxetine1 brand
Cephradine1 brand

Therapeutic classes

Peritoneal Dialytics · 2Mydriatics And Cycloplegics · 2Androgen · 1Skin Conditions · 1Antipsoriatics · 1Macrolides, Lincosamides And Streptogramins · 1Antidepressants · 1Solutions Affecting The Electrolyte Balance · 1Other Beta-Lactam, Cephalosporins & Penems · 1Anabolic Agents · 1Potassium Products · 1Opioids · 1

Conditions treated

Eczema/Psoriasis/Dermatitis · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official3 products · Rs 62.55 – Rs 383.46
Servaid1 products · Rs 133.5 – Rs 133.5
Median across source: Rs 312.82

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Get the full profile for LCPW

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.